FibroBiologics, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $0.84
- 52-Week Range
- $0.62 – $9.60
- Market Cap
- $7.46M
- P/E (TTM)
- —
- EPS (TTM)
- -2.51
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 3.82
- PEG Ratio
- —
- Return on Equity
- -1696.90%
- Return on Assets
- -127.15%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 1.22
- Debt/Equity
- 0.70
- Total Debt
- $1.27M
- Free Cash Flow
- $-7.64M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $7.66M
Market Snapshot
About
FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing cell-based therapies using fibroblast cells. The company's proprietary platform technology leverages the regenerative properties of fibroblasts to treat degenerative diseases, cancer, and wound healing applications. FibroBiologics is developing a pipeline of therapeutic candidates targeting conditions including multiple sclerosis, degenerative disc disease, and various oncology indications. The company's approach seeks to harness the immunomodulatory and tissue-regenerative capabilities of fibroblast cells to address unmet medical needs across multiple therapeutic areas.